Synthetic high-density lipoprotein-like nanoparticles as cancer therapy

Kaylin M. McMahon, Linda Foit, Nicholas L. Angeloni, Francis J. Giles, Leo I. Gordon, C. Shad Thaxton*

*Corresponding author for this work

Research output: Contribution to journalArticle

38 Scopus citations


High-density lipoproteins (HDL) are diverse natural nanoparticles that carry cholesterol and are best known for the role that they play in cardiovascular disease. However, due to their unique targeting capabilities, diverse molecular cargo, and natural functions beyond cholesterol transport, it is becoming increasingly appreciated that HDLs are critical to cancer development and progression. Accordingly, this chapter highlights ongoing research focused on the connections between HDL and cancer in order to design new drugs and targeted drug delivery vehicles. Research is focused on synthesizing biomimetic HDL-like nanoparticles (NP) that can be loaded with diverse therapeutic cargo (e.g., chemotherapies, nucleic acids, proteins) and specifically targeted to cancer cells. Beyond drug delivery, new data is emerging that HDL-like NPs may be therapeutically active in certain tumor types, for example, B cell lymphoma. Overall, HDL-like NPs are becoming increasingly appreciated as targeted, biocompatible, and efficient therapies for cancer, and may soon become indispensable agents in the cancer therapeutic armamentarium.

Original languageEnglish (US)
Pages (from-to)129-150
Number of pages22
JournalCancer treatment and research
StatePublished - 2015


  • Cancer therapy
  • Cholesterol
  • Delivery
  • High-density lipoprotein
  • Nanotechnology
  • siRNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Synthetic high-density lipoprotein-like nanoparticles as cancer therapy'. Together they form a unique fingerprint.

  • Cite this